Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial — Roser Pinyol (2017) | RDL Network
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial
Roser Pinyol, Robert Montal, Laia Bassaganyas, Daniela Sia, Tadatoshi Takayama, Gar-Yang Chau, Vincenzo Mazzaferro, Sasan Roayaie, Han Chu Lee, Norihiro Kokudo, Zhongyang Zhang, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, Joong‐Won Park, Jordi Camps, Manel Solé, Swan N. Thung, Augusto Villanueva, Carol Peña, Gerold Meinhardt, Jordi Bruix, Josep M. Llovet
Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, Gar‐Yang Chau, Jiamei Yang, Masatoshi Kudo, Jianqiang Cai, Ronnie Tung‐Ping Poon, Kwang–Hyub Han, Won Young Tak, Han Chu Lee, Tianqiang Song, Sasan Roayaie, Luigi Bolondi, Kwan Sik Lee, Masatoshi Makuuchi, Fabrício Henrique Pereira De Souza, Marie‐Aude Le Berre, Gerold Meinhardt, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.